Additional file 2: of Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016

Ikeda, Satoshi; Kato, Terufumi; Ogura, Takashi; Sekine, Akimasa; Oda, Tsuneyuki; Masuda, Noriyuki; Igawa, Satoshi; Katono, Ken; Otani, Sakiko; Yamada, Kouzo; Saito, Haruhiro; Kondo, Tetsuro; Hosomi, Yukio; Nakahara, Yoshiro; Nishikawa, Masanori; Utumi, Keiko; Misumi, Yuki; Yamanaka, Takeharu; Sakamaki, Kentaro; Okamoto, Hiroaki

doi:10.6084/m9.figshare.5946055.v1

12885_2018_4150_MOESM2_ESM.docx (22.34 kB)

Additional file 2: of Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016

journal contribution

posted on 2018-03-02, 05:00 authored by Satoshi Ikeda, Terufumi Kato, Takashi Ogura, Akimasa Sekine, Tsuneyuki Oda, Noriyuki Masuda, Satoshi Igawa, Ken Katono, Sakiko Otani, Kouzo Yamada, Haruhiro Saito, Tetsuro Kondo, Yukio Hosomi, Yoshiro Nakahara, Masanori Nishikawa, Keiko Utumi, Yuki Misumi, Takeharu Yamanaka, Kentaro Sakamaki, Hiroaki Okamoto

Table S1. CEC data and treatment efficacy of 35 patients whose CEC count was measured on days 1 and 8. Abbreviations: EGFR, epidermal growth factor receptor; CEC, circulating endothelial cell; PR, partial response; SD, stable disease; PFS, progression-free survival; OS, overall survival. (DOCX 22Â kb)